Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier

Journal of Drug Targeting

Volumn 21, Issue 4, 2013, Pages 367-374

  Yuan, Yuan ^a   Wang, Weina ^a   Wang, Baolong ^a   Zhu, Haiyan ^a   Zhang, Boheng ^a   Feng, Meiqing ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Apolipoprotein A1; Doxorubicin hydrochloride; High density lipoprotein; Hydrophilic drug; Liver target

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; APOLIPOPROTEIN A1; DOXORUBICIN; EGG PHOSPHOLIPID; LIPOSOME; PHOSPHOLIPID; RECOMBINANT HIGH DENSITY LIPOPROTEIN; RECOMBINANT PROTEIN; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CELL TRANSPORT; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG RELEASE; DRUG TARGETING; ENCAPSULATION; HEMOLYSIS; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOLIPOPROTEIN A-I; CARRIER PROTEINS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEP G2 CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPOPROTEINS, HDL; LIPOSOMES; LIVER; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE;

EID: 84877156492     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.757769     Document Type: Article

References (24)

1. Meijer DKF, Jansen RW, Molema G. Drug targeting systems for antiviral agents-options and limitations. Antivir Res 1992;18:3-4.
2. Varshosaz J. The promise of chitosan microspheres in drug delivery systems. Expert Opin Drug 2007;4:263-73.
3. Rader DJ, Ikewaki K. Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models. Curr Opin Lipidol 1996;7:117-23.
4. Tall AR. Plasma high-density lipoproteins-metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379-84.
5. Wei Q, Wu MP, Chen PF, et al. Cooperation of HDL receptor and hepatic lipase in the selectives uptake of HDL(2)-CE by rat hepatic sinusoidal cells. Acta Biochim Biophys Sinica 1996;28:659-64.
6. Martinez LO, Jacquet S, Esteve JP, et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003;421:75-9.
7. Chung NS, Wasan KM. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliver Rev 2004;56:1315-34.
8. Cheng HM. Lipoproteins, anticardiolipin autoantibodies and artherosclerosis. J Intern Med 1996;240:44-5.
9. Yu AL, Lorenz RL, Haritoglou C, et al. Biological effects of native and oxidized low-density lipoproteins in cultured human retinal pigment epithelial cells. Exp Eye Res 2009;88:495-503.
10. Oda MN, Hargreaves PL, Beckstead JA, et al. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res 2006;47:260-7.
11. McConathy WJ, Nair MP, Paranjape S, et al. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anti-Cancer Drug 2008;19:183-8.
12. Zhang XB, Chen BS. Recombinant high density lipoprotein reconstituted with Apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin. Cancer Lett 2010;298:26-33.
13. Laginha KM, Verwoert S, Charrois G, Allen TM. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005;11:6944-9.
14. Jones WG. Is there a place for chemotherapy in advanced prostatic-cancer. Am J Clin Oncol-cancer 1988;11:S98-100.
15. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression. Clin Cancer Res 2004;10:7439-49.
16. Sharma P, Sharma JD. In vitro hemolysis of human erythrocytes by plant extracts with antiplasmodial activity. J Ethnopharmacol 2004;74:239-43.
17. Sun FX, Tang ZY, Liu KD, et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 1996;66:239-43.
18. Williams DL, de la Llera-Moya M, Thuahnai ST, et al. Binding and cross-linking studies show that scavenger receptor BI interacts with multiple sites in apolipoprotein A-I and identify the class A amphipathic alpha-helix as a recognition motif. J Biol Chem 2000;275:18897-904.
19. Feng MQ, Cai QS, Huang H, Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm 2008;68:688-93.
20. Kader A, Davis PJ, Kara M, Liu H. Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J Control Release 1998;55:231-43.
21. Kader A, Pater A. Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells. J Control Release 2002;80:29-44.
22. Chen W, Meng F, Cheng R, Zhong Z. pH-sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles. J Control Release 2010;142:40-6.
23. Ajees AA, Anantharamaiah GM, Mishra VK, et al. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. P Natl Acad Sci USA 2006;103:2126-31.
24. Murakami T, Tsuchida K, Hashida M, Imahori H. Size control of lipid-based drug carrier by drug loading. Mol Biosyst 2010;6: 789-91.